Streetbeat News

Products Services

RIVN

TSLA

Rivian Automotive Inc. (NASDAQ:RIVN) has opened a new 'space' in Austin, Texas, close to Tesla's gigafactory. This move is part of Rivian's strategy to compete with Tesla in the electric vehicle market. Rivian's new space will showcase its lineup, including the R1S SUV and R1T pickup truck, which compete with Tesla's Model X and Cybertruck, respectively. Rivian aims to reach positive gross profit by the end of 2024 despite current financial losses.

Portfolio Pulse from Anan Ashraf

June 14, 2024 | 9:25 am

TSLA

Tesla CEO Elon Musk announced ambitious plans for the Optimus humanoid robot, predicting a significant market share and potential $25 trillion market cap. Tesla aims to start limited production by early next year and deploy thousands of bots in its factories by 2025. Musk's optimistic projections include selling each bot for $10,000 to $20,000.

Portfolio Pulse from Anan Ashraf

June 14, 2024 | 8:40 am

MARA

RIOT

Despite miner capitulation due to Bitcoin's recent halving event, the Bitcoin market remains strong due to high demand. Shares of Marathon Digital Holdings (MARA) fell 1.53%, while Riot Platforms (RIOT) rose 3.2%. Former President Trump expressed support for U.S. Bitcoin mining.

Portfolio Pulse from Aniket Verma

June 14, 2024 | 8:36 am

BEAM

Beam Therapeutics Inc. (NASDAQ:BEAM) has reported data on its improved manufacturing process for BEAM-101, a base editing treatment for sickle cell disease, at the European Hematology Association Hybrid Congress. The optimized process is used in the BEACON Phase 1/2 clinical trial.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 8:25 am

VRTX

Vertex Pharmaceuticals presented long-term data on CASGEVY (exagamglogene autotemcel) at the EHA 2024 Congress, showcasing promising results.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 8:14 am

EDIT

Editas Medicine has released updated safety and efficacy results from the EdiTHAL trial of reni-cel in 7 patients with transfusion-dependent beta thalassemia. All patients maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-infusion. Reni-cel was well-tolerated with a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 8:12 am

PTGX

Protagonist Therapeutics presented updated long-term findings from its Phase 2 REVIVE study of Rusfertide at EHA2024, showing sustained hematocrit control.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 8:04 am

PFE

Pfizer Inc. (NYSE:PFE) announced that its drug ELREXFIO showed a median overall survival of 24.6 months in a Phase 2 study for patients with relapsed or refractory multiple myeloma.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 7:54 am

GILD

Gilead's Kite presented new data at EHA 2024 on the outpatient administration of Yescarta and Tecartus. The analysis shows that manufacturing Yescarta for second-line treatment of relapsed/refractory large B-cell lymphoma can reduce the time from leukapheresis to infusion compared to third-line+ treatment. The data builds on previous evidence linking timely infusion to better patient outcomes and supports the safety and feasibility of outpatient administration.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 7:39 am

CABA

Cabaletta Bio announced initial clinical data from Phase 1/2 RESET-Myositis and RESET-SLE trials of CABA-201, showing no serious adverse events and promising clinical benefits. The trials are ongoing with 18 sites recruiting.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 7:25 am